Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;175(14):2770-2777.
doi: 10.1111/bph.13873. Epub 2017 Jun 28.

The dynamic interaction between pain and opioid misuse

Affiliations
Review

The dynamic interaction between pain and opioid misuse

Adrianne R Wilson-Poe et al. Br J Pharmacol. 2018 Jul.

Abstract

In 2014, drug overdose surpassed automobile accidents as the number one cause of accidental death for the first time in the history of the United States. The overdose epidemic is largely driven by opioids, and genuine prescription opioid analgesics play the biggest role in this phenomenon. Despite advancements in abuse deterrent formulations, prescription drug monitoring programmes and clinical assessments for the detection of abuse potential, drug overdoses continue to escalate. The Center for Disease Control has recently issued new guidelines for opioid prescription, yet even these recommendations have their shortcomings. Furthermore, undertreated pain in patients with comorbid substance use disorder poses a major clinical challenge, particularly for patients on opioid replacement therapy. Despite the seemingly obvious interaction between the presence of pain and the abuse of pain-relieving opioids, there is surprisingly little mechanistic data to further our understanding of this vitally important topic. The need for novel pain interventions that minimize abuse liability is critical. Without a fundamental characterization of pain neurobiology and the interaction between chronic pain and the brain's reward system, we are unlikely to make progress in the alleviation of the opioid epidemic.

Linked articles: This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc.

PubMed Disclaimer

References

    1. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL (2011). Cannabinoid‐opioid interaction in chronic pain. Clin Pharmacol Ther 90: 844–851. - PubMed
    1. Albert‐Vartanian A, Boyd MR, Hall AL, Morgado SJ, Nguyen E, Nguyen VP et al. (2016). Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther 41: 371–382. - PubMed
    1. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015). The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors. Br J Pharmacol 172: 5744–5869. - PMC - PubMed
    1. Alford DP, German JS, Samet JH, Cheng DM, Lloyd‐Travaglini CA, Saitz R (2016). Primary care patients with drug use report chronic pain and self‐medicate with alcohol and other drugs. J Gen Intern Med 31: 486–491. - PMC - PubMed
    1. Al‐Hasani R, McCall JG, Shin G, Gomez AM, Schmitz GP, Bernardi JM et al. (2015). Distinct subpopulations of nucleus accumbens dynorphin neurons drive aversion and reward. Neuron 87: 1063–1077. - PMC - PubMed

Publication types

Substances